Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,210 total articles
Codexis, Inc. reported Q2 2026 revenue of $14.9 million and reiterated full-year guidance. The company highlighted advances in its ECO Synthesis® Manufacturing Platform enabling enzyme-driven stereoisomer control of siRNA, strengthening its position in RNA therapeutics manufacturing. A successful $25 million equity raise enhanced its cash position …
Spectral AI announced its Q2 2026 financial results, highlighting FDA clearance for its DeepView® System for burn indication and a strong cash position of $14 million. The company received $31.7 million in BARDA funding and is positioned to commence first commercial sales by the end of 2026. Despite a net loss of $4.2 million for the quarter, the c…
Pliant Therapeutics, a clinical-stage biotech focused on integrin therapeutics, provided a corporate update highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095 in ICI-refractory solid tumors. The company appointed experienced oncology drug development leaders to its board, showcased promising biomarker data indicating tumor …
GrowGeneration Corp., a leading supplier in controlled environment agriculture and commercial cultivation, reported a 5.5% year-over-year sales increase to $43.2 million in Q2 2026 alongside an improved net loss and positive Adjusted EBITDA. The company enhanced its proprietary brand penetration to nearly 40% of cultivation sales and strengthened i…
MacroGenics announced that Gilead Sciences has exercised its option under their 2022 collaboration agreement to exclusively license a preclinical bispecific program targeting solid tumors. This action triggers a $10 million milestone payment to MacroGenics. The collaboration includes one clinical-stage and two preclinical bispecific programs, with …
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) announced its Q2 2026 financial results and corporate progress, highlighting advancements in its pipeline targeting KRAS-mutant cancers, initiation of combination clinical trials, presentation of promising preclinical data, and a cash runway expected to fund operations into 2028.
Absci Corporation announced positive interim Phase 1 data from its HEADLINE trial of ABS-201, an anti-prolactin receptor antibody targeting pattern hair loss and endometriosis. The company completed a $100 million underwritten offering with a $40 million strategic investment from Eli Lilly, bolstering cash reserves to $201.1 million, sufficient to …
Anterix Inc. announced its fiscal 2027 first quarter results, highlighting $33.1 million of contracted proceeds outstanding, $15.7 million received from customers, and a gain of $10.7 million from exchanging narrowband for broadband licenses. The company maintains a strong balance sheet with $116 million in cash, no debt, and an authorized share re…
Mobia Medical, a medical device company specializing in stroke recovery technologies, reported a robust second quarter 2026 with $13.5 million revenue, up 102% year-over-year, and gross margin of 83.2%. The company completed its IPO, raising $134 million in net proceeds, strengthening its cash position to $177.1 million. It also announced publicati…
Insight Molecular Diagnostics (IMDX) announced a virtual key opinion leader event featuring prominent experts to discuss the GraftAssure platform, which utilizes digital PCR technology to enable rapid and reliable donor-derived cell-free DNA testing for transplanted organ health monitoring. The GraftAssureDx test kit is currently under FDA review t…
Nasdaq announced its end-of-month short interest data as of July 31, 2026. The report shows a slight decrease in the total shares sold short in both the Nasdaq Global Market and Nasdaq Capital Market compared to the prior reporting period. The days to cover metric has modestly increased, indicating a slight change in market shorting trends.
Comscore has announced a comprehensive ROI Strategy aimed at transforming its business by realigning operations, optimizing organizational efficiency, and investing in future growth areas. The plan includes reducing annual costs by $20 to $25 million through restructuring and headcount reduction, simplifying operations, improving product developmen…
Factorial Energy Inc., a Nasdaq-listed company specializing in solid-state battery technology, announced its financial and business results for Q2 2026. The company highlighted its leadership in the development of scalable solid-state batteries for aerospace, energy storage, and mobility applications, supported by significant partnerships with majo…
Inuvo, Inc. reported its Q2 2026 financial results, highlighting a 19% year-over-year growth in Audience Modeling revenue driven by new client wins and increased investment from existing customers. However, total net revenue declined 67% due to an 80% decrease in Legacy Search revenue. The company took strategic steps to reduce costs associated wit…
High Roller Technologies reported its Q2 2026 financials, marked by a revenue decline due to strategic market exits and a focus on prediction markets. The company achieved significant regulatory milestones for its ROLR prediction platform, gaining approval as a member of the National Futures Association and planning a U.S. launch via Crypto.com der…
Firefly Aerospace has announced a two-year extension of its multi-launch agreement with Lockheed Martin to utilize the Alpha Block II rocket configuration for up to 25 launches through 2031. This upgrade enhances manufacturability, reliability, and responsiveness, allowing Firefly to meet high demand for dedicated launches in the 1,000 kg payload c…
Hour Loop, Inc., a U.S.-based online retailer, announced its second quarter 2026 financial results with net revenues increasing 25% year-over-year to $33.9 million. Despite higher revenues, net income slightly declined to $1.1 million from $1.2 million, reflecting margin pressures and increased costs. The company continues to invest in inventory an…
Mobile Infrastructure Corporation reported its second quarter 2026 financial results with same-location revenue growth of 5.6% year-over-year and contract parking volumes increasing approximately 12%. Despite a slight decrease in total revenue due to recent asset sales, same-location net operating income rose 12%. The company paid down $4.5 million…
SELLAS Life Sciences reported its Q2 2026 financial results, highlighting progress in its lead cancer drug candidates GPS and SLS009, both targeting acute myeloid leukemia (AML). The Phase 3 REGAL trial for GPS is nearing the critical 80th event for final analysis, potentially leading to FDA Biologics License Application submission. The Phase 2 tri…
H&R Block reported fiscal 2026 financial results showcasing a 5% revenue increase to $3.95 billion, a 21% rise in net income from continuing operations, and a 29% increase in earnings per share. The company returned $714 million to shareholders through dividends and share repurchases, raising its quarterly dividend by 10%. For fiscal 2027, it proje…
Mineralys Therapeutics announced its second quarter 2026 financial results, including a strengthened balance sheet following a $150 million public offering and a $100 million tranche drawn on a $500 million term loan. The company is on track for FDA's PDUFA target date of December 22, 2026, for lorundrostat, an aldosterone synthase inhibitor target…
Seer, Inc., a proteomics technology company, announced its second quarter 2026 financial results, reporting $3.1 million in revenue, a 23% decline year-over-year, driven by macroeconomic challenges and elongated sales cycles. Despite the revenue decline, gross margin remained solid at 49%, operating expenses and net loss decreased compared to the p…
Kyverna Therapeutics reported Q2 2026 financial results and significant clinical and regulatory progress for its lead CAR T-cell therapy candidate, miv-cel, targeting neurologic autoimmune diseases. The FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis, highlighting promising clinical data. The company …
Inhibikase Therapeutics announced its Q2 2026 financial results, highlighting significant progress in its Phase 3 IMPROVE-PAH clinical trial for IKT-001, a novel oral treatment for Pulmonary Arterial Hypertension (PAH). The company secured regulatory approvals in 26 countries, initiated 43 clinical sites globally, and obtained Orphan Drug Designati…
Belite Bio announced FDA acceptance and Priority Review of its New Drug Application for tinlarebant, a novel oral therapy intended to treat Stargardt Disease Type 1 (STGD1), a rare inherited retinal disease. The NDA submission is supported by positive Phase 3 DRAGON trial results demonstrating a 35.7% reduction in atrophic retinal lesion growth rat…
